Loading... Please wait... Loading... Please wait...
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
PulseVet ® Shock Wave Device Supports Equine Athletes Ahead of Major International Team Events ANN ARBOR, MI / ACCESSWIRE / July 1, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Compa...
First-of-its-kind stall-side testing to enable rapid, life-saving decisions for equine veterinarians ANN ARBOR, MI / ACCESSWIRE / June 27, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the ...
CE mark enables launch of the TRUFORMA® Diagnostic Platform into the European Union ANN ARBOR, MI / ACCESSWIRE / June 25, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a ve...
Recent trading activity suggests that penny stocks are in the spotlight. According to the Financial Times, stocks priced below $1 have comprised more than 14% of 2024's trading volume thus far, illust...
ANN ARBOR, MI / ACCESSWIRE / June 10, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products f...
New research data confirms superiority of TRUFORMA's Bulk Acoustic Wave Sensor technology in diagnosing feline hyperthyroidism ANN ARBOR, MI / ACCESSWIRE / June 6, 2024 / Zomedica Corp. (NYSE American...
Timely expansion enhances capacity amidst rapid sales growth ANN ARBOR, MI / ACCESSWIRE / June 4, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company o...
OTA capability enhances introduction of new assays from rapidly expanding menu ANN ARBOR, MI / ACCESSWIRE / May 15, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinar...
Zomedica Corp. (NYSE:ZOM ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Larry Heaton - CEO Peter Donato - CFO Conference Call Participants Operator Good afternoon, ladi...
